Company:  VICAL INC (VICL)
Form Type:  10-K
Filing Date:  2/14/2014 
CIK:  0000819050 
Address:  10390 PACIFIC CENTER COURT
.
 
City, State, Zip:  SAN DIEGO, California 92121-4340 
Telephone:  858-646-1100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.47  
Change: 
-0.13 (-2.83%)  
Trade Time: 
Jun 24  
Market Cap: 
$41.13M
Trade VICL now with 

© 2016  
Description of Business
We research and develop biopharmaceutical products, including those based on our patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. We currently have four active, independent or partnered, development programs in the area of infectious disease comprised of: · An ongoing Phase 3 clinical trial of ASP0113 for prevention of cytomegalovirus, or CMV, reactivation in hematopoietic stem cell transplant recipients and an ongoing Phase 2 clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients, both in collaboration with Astellas Pharma Inc., or Astellas. Astellas expects enrollment in the Phase 3 clinical trial to be completed during the third quarter of 2016.
Register and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
        NAME AND TITLE
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
        Liquidity and Capital Resources
          BALANCE SHEET
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
        Report of Independent Registered Public Accounting Firm
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO FINANCIAL STATEMENTS
          BALANCE SHEET
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES
      Report of Independent Registered Public Accounting Firm
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 11. EXECUTIVE COMPENSATION
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
    Report of Independent Registered Public Accounting Firm
    SIGNATURES
  EXHIBIT 10.7
  EXHIBIT 10.8
  EXHIBIT 10.9
  EXHIBIT 10.10
  EXHIBIT 10.11
  EXHIBIT 10.12
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO